scholarly journals CALCB rs3829222 T/T Genotype and Low Expression of CALCB Are High-Risk Factors for Adenoid Cystic Carcinoma of Salivary Gland

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Chaobin Dai ◽  
Bin Zhang ◽  
Yunyang Liao ◽  
Qicai Liu ◽  
Feiguang Wu ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Adenoid Cystic Carcinoma ◽  
Normal Control ◽  
Calcitonin Gene Related Peptide ◽  
Normal Control Group ◽  
Control Group ◽  
Salivary Adenoid Cystic Carcinoma ◽  
Related Peptide ◽  
Adenoid Cystic ◽  
Calcitonin Gene

Objectives. To investigate the relationship between polymorphisms of calcitonin-related peptide gene II (beta-calcitonin gene-related peptide (βCGRP), CALCB) and serum CGRP levels in salivary adenoid cystic carcinoma. Materials and Methods. Using the polymerase chain reaction (PCR) technique, the full-length amplification and genotype analysis of CALCB genes were performed in 39 patients with adenoid cystic carcinoma of salivary gland and 158 normal controls. The gene frequencies of major genotype of CALCB in adenoid cystic carcinoma of salivary gland and normal control group were analyzed. Enzyme-linked immunosorbent assay (ELISA) was used to evaluate serum calcitonin gene-related peptide (CGRP) and its concentration of alpha and beta subtypes. Results. Univariate logistic regression analysis showed that the CALCB rs2839222 T/T genotype was closely related to the occurrence of salivary adenoid cystic carcinoma, with a correlation coefficient of 3.89. Conclusions. The serum CGRP concentration in the salivary adenoid cystic carcinoma group was 1.56 times that of the normal control group. The αCGRP subtype was significant, which was 3.02 times that of the normal control. The polymorphism of βCGRP gene is associated with genetic susceptibility to salivary adenoid cystic carcinoma, and serum CGRP and βCGRP can be used as novel markers of salivary adenoid cystic carcinoma.

scholarly journals Calcitonin Gene-Related Peptide Influences Bone-Tendon Interface Healing Through Osteogenesis: Investigation in a Rabbit Partial Patellectomy Model

2021 ◽  
Vol 9 (7) ◽  
pp. 232596712110039
Author(s):  
Huabin Chen ◽  
Hongbin Lu ◽  
Jianjun Huang ◽  
Zhanwen Wang ◽  
Yang Chen ◽  
...  
Keyword(s):  
Raman Spectroscopy ◽  
Bone Mineral ◽  
Calcitonin Gene Related Peptide ◽  
Control Group ◽  
Mineral Density ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
Partial Patellectomy ◽  
Antagonist Group ◽  
Cgrp Antagonist

Background: Calcitonin gene-related peptide (CGRP), which has been shown to play an important role in osteogenesis during fracture repair, is also widely distributed throughout the tendon and ligament. Few studies have focused on the role of CGRP in repair of the bone-tendon interface (BTI). Purpose: To explore the effect of CGRP expression on BTI healing in a rabbit partial patellectomy model. Study Design: Controlled laboratory study. Methods: A total of 60 mature rabbits were subjected to a partial patellectomy and then randomly assigned to CGRP, CGRP-antagonist, and control groups. In the CGRP-antagonist group, the CGRP receptor antagonist BIBN4096BS was administered to block CGRP receptors. The patella–patellar tendon complex was harvested at 8 and 16 weeks postoperatively and subjected to radiographic, microlaser Raman spectroscopy, histologic, and biomechanical evaluation. Results: Radiographic data showed that local CGRP expression improved the growth parameters of newly formed bone, including area and volumetric bone mineral density ( P < .05 for both). Raman spectroscopy revealed that the relative bone mineral composition increased in the CGRP group compared with in the control group and the CGRP-antagonist group ( P < .05 for both). Histologic testing revealed that the CGRP group demonstrated better integration, characterized by well-developed trabecular bone expansion from the residual patella and marrow cavity formation, at the 8- and 16-week time points. Mechanical testing demonstrated that the failure load, ultimate strength, and stiffness in the CGRP group were significantly higher than those in the control group ( P < .05 for all), whereas these parameters in the CGRP-antagonist group were significantly lower compared with those in the control group at 16 weeks after surgery ( P < .05 for all). Conclusion: Increasing the local concentration of CGRP in the early stages of BTI healing enhanced osteogenesis in a rabbit partial patellectomy model and promoted healing of the BTI injury, whereas treatment using a CGRP antagonist had the opposite effect. However, exogenous CGRP expression did not induce novel bone remolding. Clinical Relevance: CGRP may have potential as a new therapy for BTI injuries or may be added to postoperative regimens to facilitate healing.

scholarly journals Comparative evaluation of serum calcitonin gene related peptide level in patients with migraine headache with and without aura

2021 ◽  
Author(s):  
Mostafa Rezaee ◽  
Nahid Ashja zadeh ◽  
Sadegh Izedi ◽  
Farinaz Fakhri
Keyword(s):  
Correlation Coefficient ◽  
Rank Correlation ◽  
Calcitonin Gene Related Peptide ◽  
Clinical Findings ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Serum Calcitonin ◽  
Related Peptide ◽  
Spearman’S Rank Correlation ◽  
Calcitonin Gene

Abstract Background During a migraine attack, trigeminal activation results in the release of calcitonin gene-related peptide (CGRP), which stimulates the release of inflammatory cytokines playing an important role in migraine. We analyze the serum level of CGRP between two groups of migrainous patients (with aura and without aura) Materials and Methods Thirty six migraine patients (included 18 patients with aura and 18 without aura) additionally 18 healthy volunteers consisted control group were selected from the clinic of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran, between March 2020 and November 2020. The CGRP level were determined from the sera of patients with migraine and control subjects by enzyme-linked immunosorbent assay kits. Spearman's rank correlation coefficient was also determined to calculate the correlation between CGRP and clinical findings. Results The level of CGRP in groups were significantly different between groups (P = 0.00). Also, the level of CGRP in aura group were significantly higher than non-aura group (P = 0.045). The Spearman’s correlation coefficient revealed a positive and significant correlation between the CGRP concentration and age (p = 0.042, r = 0.172), BMI (p = 0.013, r = 0.08), VAS (P = 0.006 ,r = 0.09), frequency of attacks (p = 0.005, r = 0.9), duration of each attack (p = 0.016, r = 0.23), Migraine Disability Assessment Scale.(p = 0.00, r = 0.785), average of number of Medication (p = 0.00, r = 0.694). However, no significant correlation was observed with gender. (P > 0.05 ) Conclusions In our study, we found migraine patients had a higher CGRP level than healthy controls and the level of CGRP was related significantly with the duration, BMI, frequency of headache, age, number of headaches per day. In conclusion, our results confirmed that CGRP may be involved in the pathogenesis of migraine attacks and related with the multiple clinical characteristics.

Diagnostic value of migraine biomarker — calcitonin-gene-related peptide

2021 ◽  
Author(s):  
O. Y. Dubenko ◽  
A. G. Chernenko
Keyword(s):  
Serum Level ◽  
Daily Activity ◽  
Episodic Migraine ◽  
Cervicogenic Headache ◽  
Calcitonin Gene Related Peptide ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
And Performance

Objective — to study the diagnostic significance of the serum level of calcitonin‑gene‑related peptide as a tool for the differential diagnosis of migraine with comorbid neck pain and tension of the pericranial muscles and cervicogenic headache. Methods and subjects. The study included 112 patients (84 women, 28 men) aged from 18 to 58 years. In 77 patients episodic migraine was diagnosed (with a typical aura in 17 and without aura in 60 patients), in 35 patients suffered from cervicalgia with muscle‑tonic syndromes and cervicogenic headache. Among patients with migraine, 42 had concomitant cervicalgia with muscle‑tonic dysfunction. The examined patients were distributed into 3 clinical groups: I — combination of episodic migraine with cervicalgia, II — episodic migraine, III — cervicalgia without migraine. In all patients, pain intensity was assessed using a visual analogue scale, the effect of migraine on daily activity and performance using the MIDAS and HIT‑6 scales, and the Neck Disability Index. The control group for comparing the serum level of CGRP consisted of 30 clinically healthy persons. The serum level of CGRP was determined by enzyme‑linked immunosorbent assay using the sandwich ELISA principle. Results. In the group of patients with a combination of episodic migraine with cervicalgia and cervicogenic headache, compared with the group with isolated migraine, the number of days with headache over the last 3 months was higher (р < 0.001), the influence of headache on daily activity and performance according to the MIDAS scales and HIT‑6 was more significant (both р < 0.001) and the number of combined analgesics used was higher (р < 0.001). Plasma level of CGRP was statistically significantly higher in patients with episodic migraine compared with the group with cervicalgia without migraine (р < 0.05), where it did not differ from the control. The CGRP level was statistically significantly higher in women with migraine compared to men (р < 0.001), but did not differ in patients with migraine with and without aura (р > 0.05). Conclusions. The serum level of calcitonin‑gene‑related peptide is a reliable diagnostic and differential diagnostic laboratory biomarker of episodic migraine. The presence of concomitant cervicalgia in patients with episodic migraine significantly affects the level of CGRP in the blood plasma and the course of the disease (an increase in the number of days with headache, the amount of analgesic use, decreased performance and daily activity).  

Immunohistochemical characterization of calcitonin gene-related peptide in the trigeminal system of the familial hemiplegic migraine 1 knock-in mouse

Cephalalgia ◽  
2011 ◽  
Vol 31 (13) ◽  
pp. 1368-1380 ◽  
Author(s):  
Rammya Mathew ◽  
Anna P Andreou ◽  
Linda Chami ◽  
Astrid Bergerot ◽  
Arn MJM van den Maagdenberg ◽  
...  
Keyword(s):  
Familial Hemiplegic Migraine ◽  
Calcitonin Gene Related Peptide ◽  
Control Group ◽  
Cell Diameter ◽  
Trigeminal Ganglia ◽  
Wild Type ◽  
Hemiplegic Migraine ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
Significant Difference

Introduction: Familial hemiplegic migraine type 1 (FHM-1) is caused by mutations in the CACNA1A gene, with the R192Q mutation being the most common. Elevated calcitonin gene-related peptide (CGRP) levels in acute migraine and clinical trials using CGRP receptor antagonists suggest CGRP-related mechanisms are important in migraine. Methods: Wild-type and R192Q knock-in mice were anaesthetized and perfused. Using immunohistochemical staining, the expression of CGRP in the trigeminocervical complex (TCC) and in the trigeminal and dorsal root ganglia was characterized. Results: There was a 38% reduction in the percentage of CGRP-immunoreactive cells in the trigeminal ganglia ( p < 0.001) of R192Q knock-in mice compared to wild-type animals. The size distribution profile of CGRP-immunoreactive cells within the trigeminal ganglia demonstrated no significant difference in cell diameter between the two groups ( p ≥ 0.56). CGRP expression was also reduced in thoracic ganglia of R192Q knock-in mice (21% vs. 27% in wild-type group; p < 0.05), but not in other ganglia. In addition, decreased CGRP immunoreactivity was observed in the superficial laminae of the TCC in R192Q knock-in mice, when compared to the control group ( p < 0.005). Conclusion: The data demonstrates that the FHM-1 CACNA1A mutation alters CGRP expression in the trigeminal ganglion and TCC. This suggests further study of these animals is warranted to characterize better the role of these mutations in the neurobiology of migraine.

Low Serum Calcitonin Gene-Related Peptide Level is Associated with Severity of Coronary Stenosis

2021 ◽  
Vol 44 (4) ◽  
pp. E23-30
Author(s):  
Xian-Feng Dong ◽  
Jia-Xin Zhong ◽  
Yuan-Ming Yan ◽  
Ming-Fang Ye ◽  
Qiong Jiang ◽  
...  
Keyword(s):  
Coronary Stenosis ◽  
Cardiovascular Events ◽  
Calcitonin Gene Related Peptide ◽  
Major Adverse Cardiovascular Events ◽  
Control Group ◽  
Syntax Score ◽  
Serum Calcitonin ◽  
Negatively Associated ◽  
Related Peptide ◽  
Calcitonin Gene

Purpose: To evaluate the relationship between the serum calcitonin gene-related peptide (CGRP) level and severity of coronary stenosis. Methods: A total of 233 eligible patients who underwent coronary angiography were divided into two groups: a control and a coronary heart disease (CHD) group. The angiographic severity of coronary stenosis was evaluated by SYNTAX and Gensini scores. The incidence of major adverse cardiovascular events within two years was collected. Results: A negative correlation between serum CGRP levels and Gensini scores was observed in all patients (r=-0.352, p<0.001), the control group (r=-0.422, p<0.001) and the CHD group (r=-0.393, p<0.001). Serum CGRP levels were negatively associated with SYNTAX scores in the CHD group (r=-0.522, p<0.001). The area under the curve of CGRP for identifying high SYNTAX scores (>22) was 0.772 [95% confidence interval (CI): 0.673-0.870, p<0.001], and for identifying high Gensini scores was 0.744 (95% CI: 0.646-0.842, p<0.001). A CGRP concentration of 25.05 pg/ml was selected as the cutoff point. A low CGRP level (<25.05 pg/ml) was an independent predictor of severe coronary stenosis, a SYNTAX score >22 [odds ratio (OR) =5.819, 95% CI: 2.240-15.116; p<0.001] and a high Gensini score (>64) (OR=4.943, 95% CI: 2.020-12.095; p<0.001). The low CGRP group had a higher incidence of major adverse cardiovascular events within two years (11.1 vs. 3.1%, p=0.031). Conclusion: In coronary atherosclerosis patients without acute myocardial injury, serum CGRP levels were negatively associated with the severity of coronary stenosis.

Comparison of protein-chip array analysis and traditional ELISAs for biomarker detection of diabetic limb arterial stenosis

Vascular ◽  
2016 ◽  
Vol 25 (3) ◽  
pp. 260-265
Author(s):  
Qiang Sun ◽  
Tao Zhou ◽  
Jun Niu ◽  
Peng Wu ◽  
Yanan Guo ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
High Sensitivity ◽  
Diabetic Control ◽  
Calcitonin Gene Related Peptide ◽  
Protein Chip ◽  
Arterial Stenosis ◽  
Control Group ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
Experimental Group

The aim of this study was to screen the biomarkers of diabetic limb arterial stenosis. Fasting blood samples of 40 patients with diabetic limb arterial stenosis (experimental group), 40 diabetes patients (diabetic control group), and 40 healthy individuals (healthy control group) were collected. Protein-chip assay analysis and ELISA were used to detect tumor necrosis factor α, interleukin-6, endothelin-1, calcitonin gene-related peptide and high-sensitivity C-reactive protein in the three groups. Protein-chip array analysis and ELISA found consistent results that endothelin-1, tumor necrosis factor α, interleukin-6 and high-sensitivity C-reactive protein in the experimental group were significantly up-regulated while the expression of calcitonin gene-related peptide was down-regulated compared with the healthy control group ( P < 0.01). When compared with the diabetic control group, only markedly increased calcitonin gene-related peptide and interleukin-6 were observed in the experimental group ( P < 0.01). The study suggests that high-throughput protein-chip may be a reliable method to screen biomarkers of diabetic limb arterial stenosis. Calcitonin gene-related peptide and interleukin-6 might be promising biomarkers for diabetic limb arterial stenosis.

Sign in / Sign up

Export Citation Format

Share Document